• About
    • Viatris in Europe
      • Unlocking European patients access to medicines
    • Viatris' Manufacturing Footprint
    • Memberships and Partnerships
    • Building Sustainable Access At Scale
  • Policy
    • Policy for Access
      • Preserving Patients Access to Off-Patent Medicines
      • Protecting Access to Essential Antibiotics
      • VAM: Improving Patient Outcomes with Existing Medicines
      • Securing Access to Critical Medicines
      • Scalable European Model Tackling Antimicrobial Resistance
    • Green Deal
      • Environmental Stewardship
    • Strategic Autonomy & Industrial Strategy
      • Investing in Supply Resilience to Secure Access
      • Best Procurement Practices
    • Digital Strategy
      • European Health Data Space
  • Public Health
    • AMR
    • NCD Academy
    • Tackling Noncommunicable Diseases
    • Advancing Access to Anaphylaxis Treatment
    • Influenza
    • Infectious Diseases
    • COVID-19
  • Conversation
Show Menu

European study shows falling prices, rising costs and shortages – findings released during World AMR Awareness Week

In the context of AMR Awareness Week, Viatris and Medicines for Europe present findings from a from an independent study by New Angle, investigating the reasons behind shortages of essential off-patent medicines, with a particular focus on antibiotics.

European study shows falling prices, rising costs and shortages – findings released during World AMR Awareness Week

The study, titled Securing access, improving lives. Strengthening patients’ access to off-patent medicines in Europe, is highlighting calls for reforms to national pricing and procurement systems to secure patient access to medicines.

Key Findings

  • Between 2020 and 2024, the average price of the top 10 off-patent antibiotics fell by 10.4%, while production costs and inflation surged.
  • Industrial producer costs increased by 31.6%, labor costs by 25.7%, and energy prices by +88% (gas) and +62% (electricity).
  • Amoxicillin prices dropped 18.9% despite being among the most affected by shortages.
  • 240 antibiotic medicines were withdrawn from the market and 385 shortages reported across 16 European countries (Shortage reports were collected from each country’s health authorities between 23rd June 2025 and 7th July 2025 and they represent shortages for a specific day).

Source: Securing access, improving lives. Strengthening patients’ access to off-patent medicines in Europe – independent study conducted by New Angle, sponsored by Viatris (2025).

 

Viatris and Medicines for Europe’s press release November 2025

Leaving the Viatris site

You are now leaving the Viatris page for a Viatris affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Viatris affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Continue
Cancel

Viatris Policy and Government Affairs

  • Privacy Notice
  • Cookie Notice
  • Terms of Use
  • Contact Us
  • Privacy Notice
    • Dutch
    • French
  • Cookie Notice
    • Dutch
    • French
  • Terms of Use
  • Contact Us
© 2025 Viatris
Created on: 6/25/2021
Updated on: 2/7/2024